{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:37Z","timestamp":1786979737089,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T00:00:00Z","timestamp":1455753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00198-016-3539-1","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T16:05:35Z","timestamp":1455811535000},"page":"2411-2421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-2293","authenticated-orcid":false,"given":"M.","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tripi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zam\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kunnathully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"key":"3539_CR1","first-page":"13","volume":"315","author":"G Krishnaswamy","year":"2006","unstructured":"Krishnaswamy G, Ajitawi O, Chi DS (2006) The human mast cell: an overview. Methods Mol Biol 315:13\u201334","journal-title":"Methods Mol Biol"},{"key":"3539_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","volume":"3","author":"M Arock","year":"2010","unstructured":"Arock M, Valent P (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 3:497\u2013516","journal-title":"Expert Rev Hematol"},{"key":"3539_CR3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(94)90153-8","volume":"15","author":"P Valent","year":"1994","unstructured":"Valent P (1994) The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 15:111\u2013114","journal-title":"Immunol Today"},{"key":"3539_CR4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","volume":"94","author":"AS Kirshenbaum","year":"1999","unstructured":"Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94:2333\u20132342","journal-title":"Blood"},{"key":"3539_CR5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11882-013-0392-6","volume":"13","author":"AJ Fried","year":"2013","unstructured":"Fried AJ, Akin C (2013) Primary mast cell disorders in children. Curr Allergy Asthma Rep 13:693\u2013701","journal-title":"Curr Allergy Asthma Rep"},{"key":"3539_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/ehm.12.12","volume":"5","author":"WR Sperr","year":"2012","unstructured":"Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261\u2013274","journal-title":"Expert Rev Hematol"},{"key":"3539_CR7","first-page":"159","volume":"3","author":"P Valent","year":"2013","unstructured":"Valent P (2013) Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 3:159\u2013172","journal-title":"Am J Cancer Res"},{"key":"3539_CR8","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.3748\/wjg.14.7005","volume":"14","author":"JK Lee","year":"2008","unstructured":"Lee JK, Whittaker SJ, Enns RA, Zetler P (2008) Gastrointestinal manifestations of systemic mastocytosis. World J Gastroenterol 14:7005\u20137008","journal-title":"World J Gastroenterol"},{"key":"3539_CR9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.23459","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A (2013) Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 88:612\u2013624","journal-title":"Am J Hematol"},{"key":"3539_CR10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5858\/arpa.2011-0325-RS","volume":"136","author":"MM Stoecker","year":"2012","unstructured":"Stoecker MM, Wang E (2012) Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 136:832\u2013838","journal-title":"Arch Pathol Lab Med"},{"key":"3539_CR11","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","volume":"116","author":"P Valent","year":"2010","unstructured":"Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116:5812\u20135817","journal-title":"Blood"},{"key":"3539_CR12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.hoc.2011.09.012","volume":"25","author":"TI George","year":"2011","unstructured":"George TI, Horny HP (2011) Systemic mastocytosis. Hematol Oncol Clin North Am 25:1067\u20131083","journal-title":"Hematol Oncol Clin North Am"},{"key":"3539_CR13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","volume":"132","author":"H Sokol","year":"2013","unstructured":"Sokol H, Georgin-Lavialle S, Canioni D et al (2013) Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol 132:866\u2013873 e1\u20133","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","volume":"34","author":"M Rossini","year":"2014","unstructured":"Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, Bonadonna P, Schena D, Escribano L, Adami S, Gatti D (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 34:383\u2013396","journal-title":"Immunol Allergy Clin North Am"},{"key":"3539_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435\u2013453","journal-title":"Eur J Clin Invest"},{"key":"3539_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","volume":"136","author":"R Zanotti","year":"2015","unstructured":"Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, Perbellini O, Rossini M, Schena D, Busa M, Marcotulli MC, Bil\u00f2 MB, Franchini M, Marchi G, Simioni L, Bonadonna P (2015) Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 136:135\u2013139","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study Group. Osteoporos Int 4:368\u2013381","journal-title":"Osteoporos Int"},{"key":"3539_CR18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","volume":"124","author":"L Escribano","year":"2009","unstructured":"Escribano L, Alvarez-Twose I, S\u00e1nchez-Mu\u00f1oz L, Garcia-Montero A, N\u00fa\u00f1ez R, Almeida J, Jara-Acevedo M, Teod\u00f3sio C, Garc\u00eda-Cos\u00edo M, Bellas C, Orfao A (2009) Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514\u2013521","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR19","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","volume":"69","author":"S Barete","year":"2010","unstructured":"Barete S, Assous N, de Gennes C, Granpeix C, Feger F, Palmerini F et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838\u20131841","journal-title":"Ann Rheum Dis"},{"key":"3539_CR20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","volume":"49","author":"M Rossini","year":"2011","unstructured":"Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880\u2013885","journal-title":"Bone"},{"key":"3539_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E Veer van der","year":"2012","unstructured":"van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67:431\u2013438","journal-title":"Allergy"},{"key":"3539_CR22","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","volume":"43","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43:1115\u20131121","journal-title":"Bone"},{"issue":"5","key":"3539_CR23","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","volume":"3","author":"O Hermine","year":"2008","unstructured":"Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palm\u00e9rini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A (2008) Case\u2013control cohort study of patients\u2019 perceptions of disability in mastocytosis. PLoS One 3(5):e2266","journal-title":"PLoS One"},{"key":"3539_CR24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166:521\u2013528","journal-title":"Br J Haematol"},{"key":"3539_CR25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","volume":"134","author":"E Veer van der","year":"2014","unstructured":"van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, van Doormaal JJ (2014) Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol 134:1413\u20131421","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0046-8177(81)80084-6","volume":"12","author":"MD Fallon","year":"1981","unstructured":"Fallon MD, Whyte MP, Teitelbaum SL (1981) Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol 12:813\u2013820","journal-title":"Hum Pathol"},{"key":"3539_CR27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1210\/jcem-72-1-140","volume":"72","author":"A Chines","year":"1991","unstructured":"Chines A, Pacifici R, Avioli LV, Teitelbaum SL, Korenblat PE (1991) Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. J Clin Endocrinol Metab 72:140\u2013144","journal-title":"J Clin Endocrinol Metab"},{"key":"3539_CR28","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","volume":"24","author":"S Seitz","year":"2013","unstructured":"Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, Minne H, Pfeiffer M, Zustin J, P\u00fcschel K, Eulenburg C, Schinke T, Amling M (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325\u20132334","journal-title":"Osteoporos Int"},{"key":"3539_CR29","first-page":"281","volume":"279","author":"C Gennes De","year":"1992","unstructured":"De Gennes C, Kuntz D, de Vernejoul MC (1992) Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 279:281\u2013291","journal-title":"Clin Orthop Relat Res"},{"key":"3539_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002920000439","volume":"22","author":"G Delling","year":"2001","unstructured":"Delling G, Ritzel H, Werner M (2001) Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 22:132\u2013140","journal-title":"Pathologe"},{"key":"3539_CR31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD (2008) Mast cells and mastocytosis. Blood 112:946\u2013955","journal-title":"Blood"},{"key":"3539_CR32","first-page":"226","volume":"58","author":"LB Schwartz","year":"1987","unstructured":"Schwartz LB (1987) Mediators of human mast cells and human mast cell subsets. Ann Allergy 58:226\u2013235","journal-title":"Ann Allergy"},{"key":"3539_CR33","first-page":"391","volume":"77","author":"JL Macpherson","year":"1989","unstructured":"Macpherson JL, Kemp A, Rogers M, Mallet AI, Toia RF, Spur B, Earl JW, Chesterman CN, Krilis SA (1989) Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 77:391\u2013396","journal-title":"Clin Exp Immunol"},{"key":"3539_CR34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","volume":"128","author":"TC Theoharides","year":"2002","unstructured":"Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344\u2013350","journal-title":"Int Arch Allergy Immunol"},{"key":"3539_CR35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","volume":"115","author":"K Brockow","year":"2005","unstructured":"Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216\u2013223","journal-title":"Clin Immunol"},{"key":"3539_CR36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","volume":"36","author":"N Chiappetta","year":"2006","unstructured":"Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32\u201336","journal-title":"Semin Arthritis Rheum"},{"key":"3539_CR37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdermsci.2007.09.009","volume":"49","author":"SJ Galli","year":"2008","unstructured":"Galli SJ, Tsai M (2008) Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 49:7\u201319","journal-title":"J Dermatol Sci"},{"key":"3539_CR38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(199710)173:1<10::AID-JCP2>3.0.CO;2-M","volume":"173","author":"C Dobigny","year":"1997","unstructured":"Dobigny C, Saffar JL (1997) H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173:10\u201318","journal-title":"J Cell Physiol"},{"key":"3539_CR39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","volume":"174","author":"M Biosse-Duplan","year":"2009","unstructured":"Biosse-Duplan M, Baroukh B, Dy M, de Vernejoul MC, Saffar JL (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174:1426\u20131434","journal-title":"Am J Pathol"},{"key":"3539_CR40","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1073\/pnas.0934373100","volume":"100","author":"LA Fitzpatrick","year":"2003","unstructured":"Fitzpatrick LA, Buzas E, Gagne TJ, Nagy A, Horvath C, Ferencz V et al (2003) Targeted deletion of histamine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 100:6027\u20136032","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3539_CR41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/187152806775269303","volume":"5","author":"L Escribano","year":"2006","unstructured":"Escribano L, Akin C, Castells M, Schwartz LB (2006) Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 5:61\u201377","journal-title":"Inflamm Allergy Drug Targets"},{"key":"3539_CR42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000048189","volume":"127","author":"AS Worobec","year":"2002","unstructured":"Worobec AS, Metcalfe DD (2002) Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 127:153\u2013155","journal-title":"Int Arch Allergy Immunol"},{"key":"3539_CR43","first-page":"45","volume":"23","author":"M Lytinas","year":"2002","unstructured":"Lytinas M, Kempuraj D, Huang M et al (2002) Azelastine\u2019s inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 23:45\u201351","journal-title":"Allergy Asthma Proc"},{"key":"3539_CR44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.exphem.2010.05.008","volume":"38","author":"E Hadzijusufovic","year":"2010","unstructured":"Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P (2010) H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol 38:896\u2013907","journal-title":"Exp Hematol"},{"key":"3539_CR45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","volume":"29","author":"PJ Turner","year":"2012","unstructured":"Turner PJ, Kemp AS, Rogers M, Mehr S (2012) Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 29:222\u2013223","journal-title":"Pediatr Dermatol"},{"issue":"suppl 100","key":"3539_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12531","volume":"70","author":"J Mullol","year":"2015","unstructured":"Mullol J, Bousquet J, Bachert C, Canonica GW, GimenezArnau A, Kowalski ML, Simons FE, Maurer M, Ryan D, Scadding G (2015) Update on rupatadine in the management of allergic disorders. Allergy 70(suppl 100):1\u201324","journal-title":"Allergy"},{"key":"3539_CR47","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.amjmed.2012.07.018","volume":"126","author":"N Guillaume","year":"2013","unstructured":"Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, Barete S, Hirsch I, Bouredji D, Royer B, Gruson B, Lok C, Sevestre H, Mentaverri R, Brazier M, Meynier J, Hermine O, Marolleau JP, Kamel S, Damaj G (2013) Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 126:75.e1","journal-title":"Am J Med"},{"key":"3539_CR48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","volume":"132","author":"A Rabenhorst","year":"2013","unstructured":"Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, F\u00f6rster A, Raap U, Wickenhauser C, Hartmann K (2013) Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 132:1234\u20131237","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR49","first-page":"672","volume":"44","author":"AS Ali","year":"2006","unstructured":"Ali AS, Lax AS, Liljestrom M, Paakkari I, Ashammakhi N, Kovanen PT, Konttinen YT (2006) Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin Chem Lab Med 44:672\u2013674","journal-title":"Clin Chem Lab Med"},{"key":"3539_CR50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S (2013) Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121\u2013132","journal-title":"Calcif Tissue Int"},{"key":"3539_CR51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00223-015-9969-5","volume":"96","author":"M Rossini","year":"2015","unstructured":"Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, Bonifacio M, Adami S, Gatti D (2015) Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int 96:410\u2013416","journal-title":"Calcif Tissue Int"},{"key":"3539_CR52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.12.007","volume":"133","author":"M Rossini","year":"2014","unstructured":"Rossini M, Adami S, Zanotti R, Viapiana O, Idolazzi L, Biondan M, Gatti D (2014) Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 133:933\u2013935","journal-title":"J Allergy Clin Immunol"},{"key":"3539_CR53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","volume":"8","author":"T Cundy","year":"1987","unstructured":"Cundy T, Beneton MN, Darby AJ, Marshall WJ, Kanis JA (1987) Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 8:149\u2013155","journal-title":"Bone"},{"key":"3539_CR54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","volume":"36","author":"A Marshall","year":"1997","unstructured":"Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36:393\u2013396","journal-title":"Br J Rheumatol"},{"key":"3539_CR55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1359\/jbmr.2002.17.4.567","volume":"17","author":"C Brumsen","year":"2002","unstructured":"Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567\u2013569","journal-title":"J Bone Miner Res"},{"key":"3539_CR56","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","volume":"64","author":"AY Lim","year":"2005","unstructured":"Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965\u2013966","journal-title":"Ann Rheum Dis"},{"key":"3539_CR57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","volume":"26","author":"M Laroche","year":"2007","unstructured":"Laroche M, Bret J, Brouchet A, Mazi\u00e9res B (2007) Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 26:242\u2013243","journal-title":"Clin Rheumatol"},{"key":"3539_CR58","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","volume":"124","author":"M Laroche","year":"2011","unstructured":"Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124:776\u2013778","journal-title":"Am J Med"},{"key":"3539_CR59","doi-asserted-by":"crossref","first-page":"1127.e1","DOI":"10.1016\/j.amjmed.2014.06.015","volume":"127","author":"M Rossini","year":"2014","unstructured":"Rossini M, Zanotti R, Viapiana O, Tripi G, Idolazzi L, Biondan M, Orsolini G, Bonadonna P, Adami S, Gatti D (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127:1127.e1\u20134","journal-title":"Am J Med"},{"key":"3539_CR60","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial. Bone 50:1389\u20131393","journal-title":"Bone"},{"key":"3539_CR61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","volume":"98","author":"IR Reid","year":"2013","unstructured":"Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S (2013) Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J Clin Endocrinol Metab 98:557\u2013563","journal-title":"J Clin Endocrinol Metab"},{"key":"3539_CR62","first-page":"1","volume":"14","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami G, Adami S, Viapiana O, Gatti D (2016) Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf 14:1\u201312","journal-title":"Expert Opin Drug Saf"},{"key":"3539_CR63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","volume":"72","author":"R Weide","year":"1996","unstructured":"Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72:41\u201343","journal-title":"Ann Hematol"},{"key":"3539_CR64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/rheumatology\/35.9.898","volume":"35","author":"T Lehmann","year":"1996","unstructured":"Lehmann T, Beyeler C, L\u00e4mmle B et al (1996) Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 35:898\u2013900","journal-title":"Br J Rheumatol"},{"key":"3539_CR65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","volume":"114","author":"JH Butterfield","year":"2005","unstructured":"Butterfield JH (2005) Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 114:26\u201340","journal-title":"Acta Haematol"},{"key":"3539_CR66","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","volume":"69","author":"P Valent","year":"2014","unstructured":"Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M (2014) Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 69:1267\u20131274","journal-title":"Allergy"},{"key":"3539_CR67","first-page":"1471","volume":"35","author":"CC Chen","year":"1994","unstructured":"Chen CC, Andrich MP, Mican JM, Metcalfe DD (1994) A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med 35:1471\u20131475","journal-title":"J Nucl Med"},{"key":"3539_CR68","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/jbmr.49","volume":"25","author":"RT Turner","year":"2010","unstructured":"Turner RT, Iwaniec UT, Marley K, Sibonga JD (2010) The role of mast cells in parathyroid bone disease. J Bone Miner Res 25:1637\u20131649","journal-title":"J Bone Miner Res"},{"key":"3539_CR69","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","volume":"121","author":"A Pardanani","year":"2013","unstructured":"Pardanani A (2013) How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 121:3085\u20133094","journal-title":"Blood"},{"key":"3539_CR70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344:307\u2013309","journal-title":"N Engl J Med"},{"key":"3539_CR71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","volume":"90","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S (2013) Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90:89\u201398","journal-title":"Eur J Haematol"},{"key":"3539_CR72","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.5650051104","volume":"5","author":"L Graves 3rd","year":"1990","unstructured":"Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP (1990) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 5:1113\u20131119","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3539-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3539-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3539-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T14:50:38Z","timestamp":1600181438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3539-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3539"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3539-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]}}}